Company intelligence / Profile preview
Alder Therapeutics
Solna, Stockholm County, Swedenaldertx.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Preclinical
01
Overview
Alder Therapeutics AB, founded in Sweden in 2022, develops allogeneic pluripotent stem cell therapies using its proprietary AlderEdge™ platform. The company’s two main programs target high unmet needs—Retinitis Pigmentosa with a mutation-independent retinal cell therapy (ALD01), and chronic heart failure with a cardiac cell therapy (ALD02). Both programs have shown strong preclinical data. ALD01 aims to enter clinical trials by 2026 pending further funding. The company has raised €3 million seed funding from Flerie and Linc and seeks additional capital to advance its pipeline.
- Therapeutic areas
- CardiovascularOphthalmology
- Modalities
- Allogeneic pluripotent stem cell (PSC) therapiesRetinal cell therapy (ALD01)Cardiac cell therapy (ALD02)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Duke-NUS Medical School (licensed technology)Flerie Invest AB & Linc AB as key investors/funders
Beyond the preview
Go deeper on Alder Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alder Therapeutics.